In Vivo Models for Incretin Research: From the Intestine to the Whole Body
- PMID: 26996422
- PMCID: PMC4803560
- DOI: 10.3803/EnM.2016.31.1.45
In Vivo Models for Incretin Research: From the Intestine to the Whole Body
Abstract
Incretin hormones are produced by enteroendocrine cells (EECs) in the intestine in response to ingested nutrient stimuli. The incretin effect is defined as the difference in the insulin secretory response between the oral glucose tolerance test and an isoglycemic intravenous glucose infusion study. The pathophysiology of the decreased incretin effect has been studied as decreased incretin sensitivity and/or β-cell dysfunction per se. Interestingly, robust increases in endogenous incretin secretion have been observed in many types of metabolic/bariatric surgery. Therefore, metabolic/bariatric surgery has been extensively studied for incretin physiology, not only the hormones themselves but also alterations in EECs distribution and genetic expression levels of gut hormones. These efforts have given us an enormous understanding of incretin biology from synthesis to in vivo behavior. Further innovative studies are needed to determine the mechanisms and targets of incretin hormones.
Keywords: Bariatric surgery; Enteroendocrine cells; Incretins.
Conflict of interest statement
Figures

Similar articles
-
Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.Dan Med J. 2015 Sep;62(9):B4860. Dan Med J. 2015. PMID: 26324089 Clinical Trial.
-
Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1144-50. doi: 10.1152/ajpendo.00571.2005. Epub 2006 Feb 14. Am J Physiol Endocrinol Metab. 2006. PMID: 16478775
-
Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers.Diabetes Metab Res Rev. 2013 Nov;29(8):655-63. doi: 10.1002/dmrr.2441. Diabetes Metab Res Rev. 2013. PMID: 23904405 Clinical Trial.
-
Incretin hormones and beta cell function in chronic pancreatitis.Dan Med Bull. 2010 Jul;57(7):B4163. Dan Med Bull. 2010. PMID: 20591345 Review.
-
Unraveling the science of incretin biology.Eur J Intern Med. 2009 Jul;20 Suppl 2:S303-8. doi: 10.1016/j.ejim.2009.05.012. Epub 2009 Jun 21. Eur J Intern Med. 2009. PMID: 19580949 Review.
Cited by
-
Articles in Endocrinology and Metabolism in 2016.Endocrinol Metab (Seoul). 2017 Mar;32(1):62-67. doi: 10.3803/EnM.2017.32.1.62. Endocrinol Metab (Seoul). 2017. PMID: 28345318 Free PMC article. No abstract available.
-
Fibroblast growth factor 21 is required for beneficial effects of exercise during chronic high-fat feeding.J Appl Physiol (1985). 2016 Sep 1;121(3):687-98. doi: 10.1152/japplphysiol.00456.2016. Epub 2016 Jul 21. J Appl Physiol (1985). 2016. PMID: 27445299 Free PMC article.
-
High-intensity infrasound effects on glucose metabolism in rats.Sci Rep. 2021 Aug 26;11(1):17273. doi: 10.1038/s41598-021-96796-5. Sci Rep. 2021. PMID: 34446814 Free PMC article.
References
-
- Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75–85. - PubMed
-
- Cho YM, Kieffer TJ. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm. 2010;84:111–150. - PubMed
-
- Cho YM, Fujita Y, Kieffer TJ. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol. 2014;76:535–559. - PubMed
-
- Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995;16:390–410. - PubMed
-
- Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3–S18. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources